# US 2018/0023054 A1 · Method for preparing antigen-specific cytotoxic t-cells by using activated b-cells and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023054 A1
- Document ID: US20180023054A1
- Status: Published application
- Kind: A1
- Application number: 15/720,508
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2015-03-31
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R&Db Foundation
- Inventors: Hyoung Jin KANG; Sun Ok YUN; Chang-Yuil KANG
- Web page: https://patentgrep.com/patent/US20180023054A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/235: Adenoviridae
- A61K 40/13: B-cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61K 40/46: Viral antigens
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 2501/05: Adjuvants
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2502/1107: B cells
- C12N 2502/99: genetically modified cells
- C12N 2710/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.

## Claims

### Claim 1

A method of producing antigen-specific cytotoxic T cells, comprising the steps of:
providing human peripheral blood mononuclear cells;
separating the peripheral blood mononuclear cells into B cells and other mononuclear cells;
treating the B cells with any one of biological response modifiers selected from the group consisting of alpha-galactosylceramide, alpha-glucuronosylceramide, phosphatidylinositol tetramannoside, isoglobotrihexylceramide, ganglioside GD3, phosphatidylcholine, beta-galactosylceramide, lipophosphoglycan, glycoinositol phospholipid, alpha-galactosylceramide analogs, including beta-anomer galactosylceramide and alpha-anomer galactosylceramide to produce an activated B cell;
introducing into the activated B cell an antigen polypeptide or a nucleic acid encoding an antigen to produce a activated B cells loaded with an antigen;
mixing and a first batch of the antigen-loaded activated B cell and the other mononuclear cells separated from the peripheral blood mononuclear cells to produce a first mixture of the cells;
subjecting the first mixture of the cells to a first incubation;
adding a second batch of the antigen-loaded activated B cells to the first mixture of the cells after the first incubation to produce a second mixture; and
subjecting the second mixture to a second incubation, wherein the antigen-specific cytotoxic T cell is generated during the first and the second incubation steps.

### Claim 2 (depends on 1)

The method of claim 1, wherein a cytokine is further added during the first and/or second incubation steps.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cytokine is at least one of IL-15, IL-2, IL-4, IL-7 and IL-9.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cytokine is added at a concentration of 10-100 ng/ml.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antigen is an antigen from a pathogen including a virus, a pathogenic bacterium or a parasite, or a tumor antigen.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antigen from the virus is selected from the group consisting of an Epstein-Barr virus (EBV) antigen including E1dGALMP2 or BZLF1, a cytomegalovirus (CMV) antigen including pp65 or IE1, an Adenovirus (Adv) antigen including HEXON or PENTON, an influenza virus antigen, a human papilloma virus (HPV) antigen, a vesicular stomatitis virus antigen, a hepatitis A, B, C, D or G virus antigen including a core antigen or a surface antigen, a respiratory synctytial virus antigen, a herpes simplex virus antigen, a human immunodeficiency virus antigen including GP-120, GP-160, p18, Tat, Gag, Pol or Env, and combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antigen is an EBV, CMV or Adv antigen.

### Claim 8 (depends on 7)

The method of claim 7, wherein the EBV, CMV and Adv antigens are encoded by pCK-IE1-IRES-pp65, pCK-E1dGALMP2-IRES-BZLF1 and pCK-HEXON-IRES-PENTON plasmid vectors, respectively as shown in FIGS. 8A, 8B and 8C, respectively.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antigen is a tumor antigen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tumor antigen is selected from tumor specific proteins including MAGE1 (Melanoma Associated Antigen), AFP (Alpha Feto Protein) CEA (Carcinoembryonic Antige) or tyrosinase, tumor-specific antigens including telomerase, BCR-ABL (Abelson-Break point cluster) or RHAMM-R3 (receptor for hyaluronic acid-mediated motility), or WT1 (Wilms Tumor protein) and any mutant forms thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the tumor antigen is WT1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the WT1 is encoded by pCK-WT1 shown in FIG. 8D

### Claim 13 (depends on 1)

The method of claim 1, wherein the antigen-loaded activated B cells and the other mononuclear cells separated from the peripheral blood mononuclear cells at the first mixture or at the second mixture are present at a ratio of 1:20 to 1:1 in cell number.

### Claim 14 (depends on 1)

The method of claim 1, wherein the human peripheral blood mononuclear cells are autologous or allogeneic.

### Claim 15 (depends on 1)

A cell immunotherapeutic agent comprising the cells produced according to claim 1.
